Abivax (ABVX) Operating Income (2022 - 2026)
Abivax (ABVX) posted quarterly Operating Income of -$65.8 million for Q1 2026, down 32.59% year-over-year from -$97.7 million in Q1 2025, and up 21.12% quarter-over-quarter from -$83.5 million in Q4 2025.
Abivax (ABVX) Operating Income (2022 - 2026) Analysis & Trends
Abivax's Operating Income history runs 5 years deep, the most recent figure standing at -$65.8 million for Q1 2026.
- In Q1 2026, Operating Income fell 32.59% year-over-year to -$65.8 million; the TTM figure through Mar 2026 stood at -$296.3 million (down 57.12% YoY), while the FY2025 annual figure was -$286.5 million, down 54.96% from the prior year.
- Operating Income for Q1 2026 stood at -$65.8 million, up from -$83.5 million in the prior quarter.
- The five-year high for Operating Income was -$38.0 million in Q2 2024, with the low at -$137.1 million in Q4 2023.
- The 5-year median for Operating Income is -$55.1 million (2024), against an average of -$67.0 million.
- The sharpest annual moves came in 2023 and 2024: Operating Income sank 107.34% in 2023, then soared 66.62% in 2024.
- Abivax's Operating Income stood at -$66.1 million in 2022, then plunged by 107.34% to -$137.1 million in 2023, then jumped by 66.62% to -$45.8 million in 2024, then plunged by 82.41% to -$83.5 million in 2025, then advanced by 21.12% to -$65.8 million in 2026.
- Business Quant data shows ABVX's Operating Income at -$65.8 million in Q1 2026, -$83.5 million in Q4 2025, and -$94.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Abivax | 9.39 Bn | 9.39 Bn | - | -65.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -65.83 Mn |
| Dec 31, 2025 | -83.45 Mn |
| Sep 30, 2025 | -94.36 Mn |
| Jun 30, 2025 | -52.63 Mn |
| Mar 31, 2025 | -49.65 Mn |
| Dec 31, 2024 | -45.75 Mn |
| Sep 30, 2024 | -55.12 Mn |
| Jun 30, 2024 | -38.04 Mn |
| Mar 31, 2024 | -48.53 Mn |
| Dec 31, 2023 | -137.07 Mn |
| Dec 31, 2022 | -66.11 Mn |